title: Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release.
abstract: Intravenous administration of recombinant human interleukin 1 beta (IL-1 beta, 1 micrograms/100 g body wt) resulted in a marked elevation of plasma adrenocorticotropic hormone (ACTH) levels, with peak levels at 10 min, in conscious unrestrained rats. One week after the placement of a lesion by radiofrequency or microinjection of kainic acid in the organum vasculosum of lamina terminalis (OVLT) but not in subfornical organ, ACTH response to intravenous IL-1 beta was enhanced, whereas both radiofrequency-induced lesion and kainic acid in the preoptic area (POA) suppressed the response. Indomethacin or a prostaglandin E (PGE) antagonist microinjected into the OVLT or POA suppressed or abolished the response. On the other hand, PGE, but not PGD2, microinjected into the POA increased plasma ACTH levels. These results suggest an important role for the OVLT, which lacks blood-brain barrier, as a possible site of entry of blood-borne IL-1 beta into the brain and for the POA, which may contain the neurons required for the response. Involvement of PGE in the OVLT and POA in the ACTH response to intravenous IL-1 beta is also suggested.
authors.affiliation: U.S.-Japan Biomedical Research Laboratories, Tulane University Hebert Center, Belle Chasse 70037.
authors.forename: G
authors.initials: G
authors.lastname: Katsuura
authors.forename: A
authors.initials: A
authors.lastname: Arimura
authors.forename: K
authors.initials: K
authors.lastname: Koves
authors.forename: P E
authors.initials: PE
authors.lastname: Gottschall
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism*; D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide / Q000008:administration & dosage / Q000494:pharmacology; D015232:Dinoprostone / Q000008:administration & dosage / Q000494:pharmacology; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology*; D007608:Kainic Acid / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008845:Microinjections; D008954:Models, Biological; D009490:Neurosecretory Systems / Q000502:physiology*; D011301:Preoptic Area / Q000187:drug effects / Q000502:physiology*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000008:administration & dosage / Q000494:pharmacology; D011846:Radio Waves; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D012016:Reference Values; D013238:Stereotaxic Techniques; D013356:Subfornical Organ / Q000187:drug effects / Q000502:physiology*
chemical_list: D007375:Interleukin-1; D011448:Prostaglandin Antagonists; D011994:Recombinant Proteins; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; D000324:Adrenocorticotropic Hormone; D000527:Alprostadil; D015232:Dinoprostone; D015230:Prostaglandin D2; D007608:Kainic Acid; D007213:Indomethacin